FuchsHJ, BorowitzD, ChristiansenD, MorrisE, NashM, RamseyB,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl I Med1994;331:637-42.
2.
OsterG, HuseDM, LaceyMI, ReganMM, FuchsHJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother1995;29:459-64.
3.
DrummondMF. Guidelines for pharmacoeconomic studies. Pharmacoeconomics1994;6:493-7.
4.
Canadian Coordinating Office for Health Technology Assessment (CCO-HTA).Guidelines for economic evaluation of pharmaceuticals. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1994.
5.
SacristánJA, SotoJ, GalendeI.Evaluation of pharmacoeconomic studies: the utilization of a checklist. Ann Pharmacother1993;27:1126-33.
